IDEXX Laboratories Inc (IDXX)
543.45
+2.51
(+0.46%)
USD |
NASDAQ |
May 17, 16:00
543.51
+0.06
(+0.01%)
After-Hours: 20:00
IDEXX Laboratories Enterprise Value: 45.43B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 17, 2024 | 45.43B |
May 16, 2024 | 45.22B |
May 15, 2024 | 45.85B |
May 14, 2024 | 43.59B |
May 13, 2024 | 42.09B |
May 10, 2024 | 42.65B |
May 09, 2024 | 41.91B |
May 08, 2024 | 40.77B |
May 07, 2024 | 40.49B |
May 06, 2024 | 39.93B |
May 03, 2024 | 40.24B |
May 02, 2024 | 39.85B |
May 01, 2024 | 39.20B |
April 30, 2024 | 41.24B |
April 29, 2024 | 42.28B |
April 26, 2024 | 41.78B |
April 25, 2024 | 41.09B |
April 24, 2024 | 41.51B |
April 23, 2024 | 41.47B |
April 22, 2024 | 40.29B |
April 19, 2024 | 40.02B |
April 18, 2024 | 40.14B |
April 17, 2024 | 40.18B |
April 16, 2024 | 41.12B |
April 15, 2024 | 41.26B |
Date | Value |
---|---|
April 12, 2024 | 41.80B |
April 11, 2024 | 42.24B |
April 10, 2024 | 42.33B |
April 09, 2024 | 43.63B |
April 08, 2024 | 43.20B |
April 05, 2024 | 43.60B |
April 04, 2024 | 43.48B |
April 03, 2024 | 43.98B |
April 02, 2024 | 43.78B |
April 01, 2024 | 44.67B |
March 31, 2024 | 45.29B |
March 28, 2024 | 45.34B |
March 27, 2024 | 45.31B |
March 26, 2024 | 44.56B |
March 25, 2024 | 44.49B |
March 22, 2024 | 44.57B |
March 21, 2024 | 44.69B |
March 20, 2024 | 44.47B |
March 19, 2024 | 44.88B |
March 18, 2024 | 44.50B |
March 15, 2024 | 44.49B |
March 14, 2024 | 44.98B |
March 13, 2024 | 45.36B |
March 12, 2024 | 45.91B |
March 11, 2024 | 46.03B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
16.49B
Minimum
Mar 23 2020
60.72B
Maximum
Aug 05 2021
37.98B
Average
39.76B
Median
Enterprise Value Benchmarks
Regeneron Pharmaceuticals Inc | 99.70B |
ResMed Inc | 32.88B |
Steris PLC | 25.91B |
Zoetis Inc | 84.03B |
Vertex Pharmaceuticals Inc | 104.72B |
Enterprise Value Related Metrics
Net Income (Quarterly) | 235.58M |
Revenue (Quarterly) | 964.10M |
Total Expenses (Quarterly) | 665.14M |
EPS Diluted (Quarterly) | 2.81 |
Gross Profit Margin (Quarterly) | 61.52% |
Profit Margin (Quarterly) | 24.44% |
Earnings Yield | 1.90% |
Operating Earnings Yield | 2.44% |
Normalized Earnings Yield | 1.901 |